Cancel the denosumab holiday

@article{Mcclung2016CancelTD,
  title={Cancel the denosumab holiday},
  author={Michael R Mcclung},
  journal={Osteoporosis International},
  year={2016},
  volume={27},
  pages={1677-1682}
}
Denosumab, a fully human IgG2 anti-RANK ligand antibody, quickly and substantially inhibits bone remodeling [1]. As expected by the pharmacology of denosumab, this inhibition of remodeling is completely reversible upon stopping treatment [2]. In clinical trials, discontinuing therapy after 2 years results in a rapid rebound in bone turnover markers, raising concern about whether that high remodeling rate and consequent rapid bone loss that occurs has clinical relevance beyond a simple waning of… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 4 times over the past 90 days. VIEW TWEETS
13 Citations
60 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 60 references

AbrahamsenB (2015)Denosumab: a novel antiresorptive drug for osteoporosis

  • E Suresh
  • Cleve Clin J Med
  • 2015
1 Excerpt

Similar Papers

Loading similar papers…